Biochip-images · A Breast Cancer Biomarker Point of CarePOCDiagnostic Platform Integrating Dual-Functionalized Nanoparticle for Magnetic Gradient Ranking and Electrochemical Sensing
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2019-12-01 → 2022-05-31
- Финансиране от ЕС
- 184 591 €
- Участници
- 1
- Схема
- MSCA-IF-EF-ST
Линиите свързват координатора с партньорите.
Накратко на български
Биочипът за диагностика на рак на гърдата използва магнитни наночастици за улавяне и откриване на специфични биомаркери. Разработването на такава платформа помага за по-бърза и лесна ранна диагностика на заболяването.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
A Breast Cancer Biomarker Point of CarePOCDiagnostic Platform Integrating Dual-Functionalized Nanoparticle for Magnetic Gradient Ranking and Electrochemical Sensing
This MSCA titled ‘Biochip-images’ for short aimed to implement novel approaches towards the development of a healthcare diagnostic assay capable of addressing the need for improved cross functional and adaptive therapeutics design. Now more than ever, it is clear that society stands to gain significantly from such advancements. Moreover, the recent and continued worldwide COVID-19 pandemic, and associated variants, have highlighted the clinical and societal benefits associated with early diagnosis and the importance of advanced assay development. In this project, the MSCA Fellow focused on three major objectives: 1) surface functionalisation of magnetic NPs by coating with both antibodies and redox probes to develop dual-NPs for biomarker capture and electrochemical amplification, 2) understanding the mechanisms associated with integration of PDMS microfluidic channels, towards the constructions of a novel POC device for biomarker diagnostic associated with dual-NPs and 3) initial fabrication design concepts of Mag and Me arrays to develop a microchip for Mag ranking and electrochemical sensing of MP and MB. This project has advanced the development of a new POC concept by integrating knowledge of magnetic nanoparticles (MP), advanced magnetophoresis, and a sensitive microelectrode sensing. Outcomes include; 1) Development of a novel method to isolate the target MP from the free MP, by use of a magnetic susceptibility gradient array. 2) The MP developed here has been labelled with both redox and biological properties, which allows for improved amplification as well as biomarker capture. 3) As a POC concept, the device could combine both the magnetic susceptibility gradient array and electrode array, enabling simplification of the sampling procedure and improved diagnostic efficiency (however, this would require further testing to verify). 4) Several Invention Discovery Applications (IDAs) have been submitted to the University. A parallel objective of the MSCA Individual Fellowship is to foster the development and progression of the individual researcher which is also report on below. In undertaking this MSCA, it has provided the Fellow with a framework to conduct this project within the top university of University College Dublin (UCD), working with access to world-class expertise within the Centre for Bio-Nano Interactions. Here the Fellow gained significant experience and knowledge not only within the core research objectives but also in project management, scientific writing, and proposal development. Following the conclusion of MSCA, the Fellow has secured a role as a senior scientist in LumraDx based in the UK, and has been able to utilise the knowledge and skills gained during the project towards the development of COVID ultra diagnostic assays within the Research and Development Department.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
Breast cancer is the most common neoplasm in women and the second leading cause of cancer-related mortality in females worldwide, with 25.1% of incidence and 14.7% of mortality across all cancers. A convenient blood-based tumor marker test has the potential to underpin a significant improvement in early intervention.In this context, this proposal is concerned with development of a new point of care (POC) device for biomarker detection by exploiting a combination of state of the art magnetophoresis, electroanalysis, nanotechnology, and microfluidic integration. In the POC device, dual-functionalized magnetic nanoparticles (dual-NPs) with antibodies and redox probes will be capable of selectively recruiting specific markers from real patient samples and will additionally underpin amplified redox probes for detection. Second, using a magnetic gradient chip, composed of both magnetic gradient (Mag) and microelectrode (Me) arrays, the exerted magnetic gradient field will be capable of separating dual-NPs labeling biomarkers (MBs) from free dual-NPs (MPs) to be positioned at distinct sensing zone of micro-electrode, prior to assay. Herein, only those biomarkers hosted by dual-NPs, will be reported electrochemically for quantification.Three primary objectives are proposed by the candidate: i) development of dual-NPs combining immunological recognition and electrochemical amplification properties, ii) fabrication of Mag chip engineering Mag and Me arrays for magnetic gradient ranking and electrochemical sensing, iii) integration of POC platform with Mag and Me arrays, dual-NPs and microchannels, for cancer biomarker diagnosis.As a proof-of-concept, the developed POC device will be applied to the detection and quantification of breast cancer markers (CA15-3, PAI-1 and HSP90A) in a small (<20µL) blood serum. The detection limit of this device is expected to be ng/ml quantities and duration is estimated to 15 mins for each test with blood serum.
Оригинален текст от CORDIS (на английски).
Участници
- UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN · DublinКоординаторИрландия
Връзки
Данни: CORDIS, © Европейски съюз
